Aims/hypothesis Previous studies have demonstrated that high-affinity insulin-binding B cells (IBCs) silenced by anergy in healthy humans lose their anergy in islet autoantibody-positive individuals with recent-onset type 1 diabetes, and in autoantibody-negative first-degree relatives carrying certain risk alleles. Here we explore the hypothesis that IBCs are found in the immune periphery of disease-resistant C57BL/6-H2g7 mice, where, as in healthy humans, they are anergic, but that in disease-prone genetic backgrounds (NOD) they become activated and migrate to the pancreas and pancreatic lymph nodes, where they participate in the development of type 1 diabetes. Methods We compared the status of high-affinity IBCs in disease-resistant VH125.C57BL/6-H2g7 and disease-prone VH125.NOD mice.
Introduction
Although T cells are the primary pathogenic effectors in type 1 diabetes, mounting evidence indicates that B lymphocytes play an essential role in disease development [1] [2] [3] [4] [5] . The mechanism by which B cells contribute to type 1 diabetes remains elusive, but B cell receptor (BCR) antigen specificity for islet autoantigen has been shown to be essential [6, 7] . Interestingly, although anti-islet antibodies may play a role [8] , they are not required for disease development [9] . Studies in the NOD mouse model of diabetes indicate that B cells are necessary for islet antigen presentation to both CD4 and CD8 T cells [10, 11] .
The action of islet antigen-reactive B cells in type 1 diabetes presumably requires a breach in tolerance mechanisms: receptor editing, clonal deletion and/or anergy. Recent studies in humans have demonstrated that high-affinity autoreactive B cells reside in the anergic compartment in healthy individuals. However, early in the development of type 1 diabetes, autoimmune thyroid Mia J. Smith and Rochelle M. Hinman contributed equally to this study. disease and systemic lupus erythematosus, autoantigen-reactive anergic B cells leave this compartment [12] [13] [14] and become activated [13] , accumulating in the target organs (M. J. Smith and J. C. Cambier, unpublished observations). Owing to the difficulty of tracking these cells and monitoring their function and participation in development of disease in humans, exploration in animal models, such as the NOD mouse, is critical.
Fixation of the B cell repertoire by immunoglobulin transgenesis has allowed the study of B cell tolerance to autoantigens, such as insulin in the Tg125 anti-insulin transgenic mouse [6] . It has been reported that in both diseasesensitive Tg125.NOD and disease-resistant Tg125.C57BL/6 mice, B cells mature normally yet are anergic based on a failure to proliferate or on an impairment of calcium flux following stimulation [15, 16] . However, unlike in other anergy models, these 'anergic' autoreactive B cells respond to BCR stimulation by upregulation of CD86, and phosphorylation of spleen tyrosine kinase (Syk) and phosphoinositide phospholipase C γ, and can act as antigen-presenting cells to T cells, findings inconsistent with an anergic status [15, [17] [18] [19] [20] . Thus the available evidence paints a muddled picture. Although mice that lack insulin-binding B cells (IBCs) have a greatly decreased incidence of disease [6] , the reportedly anergic IBCs in Tg125.NOD mice support the development of diabetes at a rate similar to that seen in NOD mice [15] . Moreover, previous studies have reported that Tg125 mice with a C57BL/6 background do not develop disease, possibly owing to IBC anergy. However, wild-type B cells on a C57BL/6 background do not carry the necessary MHCII allotype (H2g7) to support the presentation of insulin to T cells [11] . Given that Tg125 B cells on a C57BL/6 background also do not carry the necessary MHC allotype, their use as a model of type 1 diabetes development is limited. Finally, in Tg125 mice IBCs are not starved by normal competition for survival factors, decreasing their relevance as a model for B cell tolerance.
This study explores these questions using a more physiological model in which 1-2% of B cells are insulin reactive by virtue of transgenic expression of the VH125 heavy chain [21, 22] . This heavy chain pairs with endogenous immunoglobulin light chains to achieve repertoire diversity [6] . Results demonstrate that in diabetes-susceptible (VH125.NOD) and resistant mice carrying the same MHCII allotype (VH125.C57BL/ 6-H2g7), B cells with BCR affinity sufficiently high to sense insulin at physiological concentrations [23] are phenotypically and functionally distinct. Our results provide insight into the participation of high-affinity IBCs in type 1 diabetes.
Methods
Mice Mice expressing the IgM a heavy chain insulin-binding transgenes VH125 [Cg-Tg(Igh-6/Igh-V125)2Jwt/JwtJ] or non-insulin binding VH281 [Tg(Igh-6/Igh-V281)3Jwt/JwtJ] on NOD and C57BL/6 backgrounds were kindly supplied by J. W. Thomas (Vanderbilt University, TN, USA) [6, 15] . Mice expressing the IgM heavy chain VH281 were used as a control strain in this study since they differ from VH125 mice in that they lack IBCs in the periphery [6] . VH125.C57BL/6 mice were crossed with C57BL/6-H2g7 [B6.NOD-(D17Mit21-D17Mit10)/LtJ] (Jackson Labs, Bar Harbor, ME, USA) to create VH125.C57BL/6-H2g7 mice, which carry the same MHCII as NOD mice. Unless otherwise indicated, 8-to 12-week-old non-diabetic female mice were used for all experiments. Two consecutive blood glucose readings of over 13.88 mmol/l (OneTouch Ultramini meter, OneTouch, Wayne, PA, USA) identified the mice as diabetic. Diabetic mice were humanely euthanised. Animals were housed at National Jewish Health (Denver, CO, USA) or University of Colorado School of Medicine (Aurora, CO, USA) under specific pathogen-free conditions. Experimentation was approved by the respective Institutional Animal Care and Use committees.
Tissue processing for single-cell suspensions Splenocytes were prepared and erythrocytes lysed using ammoniumchloride-potassium lysing buffer (prepared in the Cambier lab). Pancreatic lymphocytes were isolated, as previously described [24, 25] . Briefly, the pancreases were cut into small pieces and incubated in collagenase solution for 15 min at 37°C. Cells were pipetted up and down to break up the remaining tissues, and the cells were then suspended in magnetic-activated cell sorting (MACS) buffer (Miltenyi, San Diego, CA, USA), vortexed and allowed to settle for 1 min. The suspended cells were filtered and spun down. The cell pellet was resuspended in enzyme-free cell dissociation buffer (Gibco, Waltham, MA, USA). The cells were rested at room temperature for 10 min and then spun down and stained for flow cytometric analysis.
Identification and enrichment of B cells based on BCR binding to insulin As previously described [12, 26] , cells were stained at 4°C with 0.1 μg insulin-biotin per 10 6 cells per 100 μl and antibodies (as described below) for 30 min, fixed with 2% (wt/vol.) formaldehyde and incubated with streptavidinAlexa 647 (Thermo Fisher Scientific, Waltham, MA, USA) for 15 min. Cells were then washed and incubated with anti-Cy5/ anti-Alexa 647 microbeads (Miltenyi) for 10 min and passed over magnetised LS columns (Miltenyi). Columns were washed three times, and bound cells were eluted in 6 ml of MACS buffer.
Flow cytometry analysis Cells were stained with antibodies directed against the following molecules: B220 (BD, San Jose, CA; RA3-6B2), CD19 (BioLegend, San Diego, CA, USA; 6D5) , CD21/35 (BioLegend; 7E9), CD23 (BioLegend; B3B4), CD24 (BioLegend; M1/69), CD86 (BD; GL-1), CD69 (BD; H1.2F3), CD138 (BioLegend; 281-2), λ light chains (SouthernBiotech, Birmingham, AL, USA; 1060) and IgM (Cambier lab, Aurora, CO, USA; b-7-6). Dilutions were based on the manufacturers' instructions, and specificity was verified using T cells as a negative control for B cell markers, and macrophages as a positive control for the activation marker CD86. Fluorescence minus one samples were used for compensation. Flow cytometry was performed on an LSRFortessa X-20 (BD) and data analysed with FlowJo software version 8.8 (Ashland, OR, USA).
Analysis of intracellular free calcium Splenocytes (10 7 cells/ ml) were incubated in 37°C RPMI, 2% (wt/wt) BSA and 1 μmol/l Indo-1, AM (Molecular Probes, Eugene, OR, USA) for 30 min. Anti-CD19, Fab anti-IgM and biotinylated insulin were added during Indo loading. Insulin binding was detected by staining with DyLight 650 (Thermo Fisher Scientific) Fab anti-biotin for 15 min. Fab fragments were used to avoid cell stimulation. Cells (2 × 10 6 /0.4 ml) were analysed using an LSR Fortessa X-20 flow cytometer to establish a baseline, and then stimulated with 5 μg F(ab′) 2 
Results
Identification and isolation of IBCs Experiments were made possible by the development of methodology to identify and enrich B cells that bind insulin via their BCRs [12, 26] . Figure 1a shows a representative diagram of the enrichment scheme, and demonstration of the specificity of the reaction, by competitive inhibition of the binding of biotinylated insulin with excess unlabelled insulin. Using this method, we found that IBCs from VH125.C57BL/6-H2g7 mice bound significantly less antigen than IBCs from VH125.NOD mice based on staining intensity (mean fluorescence intensity [MFI]), whether we compared magnetic particle enriched or unenriched populations (Fig. 1b, c) . This result is consistent with the possibility that IBCs in VH125.C57BL/6-H2g7 mice have downregulated membrane IgM (mIgM) receptors, consistent with anergy [27, 28] . IBC frequency is directly correlated with penetrance and rate of onset of type 1 diabetes in NOD mice If IBCs play a limiting role in the development of type 1 diabetes [6] , one would expect that disease development should correlate with IBC frequency. To explore this relationship, we analysed the rate of onset and penetrance of disease in mice that had differing frequencies of IBCs.
In VH125.NOD mice around 1-1.5% of splenic B cells bound insulin when not enriched (Fig. 1d ), compared with around 20% when they were enriched (Fig. 1e ). Similar to previous findings [6] , all of these female mice developed disease by 30 weeks of age (Fig. 2a) . In age-matched, nontransgenic female NOD mice, about one tenth the number of splenic IBCs was seen and disease onset was delayed, with 70% of mice being diabetic at 30 weeks (Fig. 2a) . The IgM heavy chain VH281 differs from VH125 in that it lacks two amino acids in CDR2, and is not permissive for insulin binding, regardless of the paired light chain [6] . No IBCs were detectable in VH281.NOD mice, and less than 5% of female VH281.NOD mice developed type 1 diabetes (Figs 1d, 2a ). The few that developed disease had lost allelic exclusion, as indicated by an expression of endogenous μ b heavy chains (data not shown). Thus disease development may have been supported by cells that acquired insulin reactivity via endogenous Ig gene usage. Interestingly, despite having more peripheral IBCs than wild-type NOD mice, VH125.C57BL/6-H2g7 mice did not develop diabetes (Figs 1d, 2a ). This suggests that these IBCs may be functionally silenced.
As shown in Fig. 2c , the female sex bias for the development of type 1 diabetes was maintained in the presence of the VH125 transgene. Although disease was observed in 100% of male VH125.NOD mice, the rate of development was statistically significantly lower than in females. The sex difference also correlated with varying frequency of splenic IBCs (Fig.  2d) . Thus sex-based factors that affect disease probably also affect the frequency of IBCs.
Taken together, these results are consistent with the possibility that the rate and penetrance of type 1 diabetes in genetically predisposed mice are determined in part by the number of IBCs present, which could be an effect of sex.
VH125.NOD mice display defects in peripheral tolerance It has previously been shown that in VH125.NOD mice immature IBCs transition from the parenchyma to the sinusoids of the bone marrow and exit to the periphery of the immune system with no reduction in number, consistent with a defect in central tolerance [29] . We wanted to determine whether these mice also show a defect in peripheral tolerance.
During our studies, we identified two discrete IBC populations in both VH125.NOD and VH125.C57BL/6-H2g7 mice that distributed on distinct diagonals when analysed for IgM expression and insulin binding (Fig. 3a) . The high IBC (Fig. 3b) . Interestingly, in VH125.C57BL6-H2g7 mice, the Insulin lo expressed higher levels of surface IgM than the right-shifted Insulin hi population (Fig. 3a, c) . This differed from the VH125.NOD mice, in which both the Insulin lo and Insulin hi B cell populations expressed high IgM levels compared with the non-IBCs (Fig. 3a, c) . Based on our studies in humans, we suspect that the Insulin lo B cell population in VH125.C57BL/6-H2g7 mice has sufficiently low insulin affinity that cells are ignorant of ambient insulin, despite being captured by the enrichment procedure [12] . On the other hand, the Insulin hi B cell population in VH125.C57BL/6-H2g7 mice has sufficiently high affinity that cells are rendered anergic, as indicated by IgM downregulation compared with non-IBCs and the Insulin lo population (Fig. 3c) . Conversely, it appears that the Insulin hi cells in VH125.NOD mice are not anergic since IgM levels remain high (Fig. 3c) .
In order to further analyse the status of these cells, we explored their history of receptor editing by analysing the ratio of λ:κ BCR light chain usage, often used as a surrogate measure of receptor editing (Fig. 3d, e) [30] . In general, the frequency of λ + cells was higher among IBCs from VH125.C57BL/6-H2g7 than VH125.NOD mice. It thus appears that fewer IBCs have . Results are representative of at least three experiments with at least three mice in each group. The mean for each group is shown as a horizontal line. *p < 0.05, **p < 0.01, ***p < 0.001, Mann-Whitney U tests undergone receptor editing in NOD mice. Moreover, the Insulin lo IBCs in the VH125.C57BL/6-H2g7 mice expressed significantly more λ light chains than their Insulin hi counterparts (Fig. 3d, e) . Again, we suggest that, in these cells, significant insulin autoreactivity has been edited away, so the cells become ignorant of their antigen.
Analysis of the relative number of IBCs in the periphery as a function of the age of the animal provided additional evidence of a difference in autoreactive B cells between the various genetic backgrounds (Fig. 3f) . The total number of splenic IBCs in VH125.NOD mice increased nearly fourfold between weaning (around 0.5 × 10 5 /spleen) and the onset of In the experiments not shown, the ΔgMFI of pSyk in IBCs from VH125.C57BL/6-H2g7 mice was on average (mean) 145 and 128 times less than that for Insulin − cells (p < 0.01 for both experiments), whereas the IBCs from VH125.NOD mice had a gMFI on average 43 and 65 times higher than that in non-IBCs (p < 0.01 and p < 0.001, respectively). Basal PTEN levels in IBCs from VH125.C57BL/6-H2g7 mice showed an average 30 and 62 times higher gMFI than non-IBCs (p < 0.05 and p < 0.01, respectively), whereas IBCs from VH125.NOD mice had on average a 22 and 37 times lower gMFI than non-IBCs (*p < 0.05 for both). For stimulation experiments, cells were stimulated with 5 μg/ml of F(ab′) 2 goat anti-mouse IgM. *p < 0.05, **p < 0.01, ***p < 0.001 determined by Mann-Whitney U test. Data in (c) and (e) are mean ± SEM ELISA of serum demonstrating that IBCs in VH125.NOD (dark grey squares), but not VH125.C57BL/6-H2g7 (black circles) mice, probably produce anti-insulin antibodies, and are increased compared with wildtype NOD (light grey triangles) mice. Insulin reactivity in the serum of VH125.NOD mice was significantly elevated compared with VH125.C57BL/6-H2g7 mice (p < 0.01). All experiments used n = 5 female, non-diabetic, 8-to 12-week-old mice. Results are representative of at least three experiments with at least three mice per group. *p < 0.05, **p < 0.01, ***p < 0.001; Mann-Whitney U tests were used for all assays except ELISA, in which a one-way ANOVA with repeated measures was used overt type 1 diabetes (around 2 × 10 5 /spleen) (Fig. 3f) , whereas no such accumulation of IBCs occurred in wild-type NOD and VH125.C57BL/6-H2g7 animals. The total number of splenic IBCs in VH125.C57BL/6-H2g7 mice remained low and constant regardless of age, consistent with a maintenance of peripheral tolerance.
To better understand their contribution to disease development, we assessed the relative numbers of B cells with high vs low insulin affinity as a function of age in the VH125.NOD mice (Fig. 3g) . The Insulin lo IBCs were present in spleen at the earliest time point examined (weaning) and increased in number until the B cell compartment matured, i.e. about 6 weeks of age. Whereas the frequency of low-affinity splenic IBCs remained relatively constant after 6 weeks of age, the frequency of Insulin hi IBCs continued to increase until the onset of diabetes (Fig. 3g) .
Next, we determined the distribution of Insulin lo and Insulin hi B cells in various splenic B cell subcompartments in the two strains. Insulin hi B cells in the VH125.C57BL/6-H2g7 mice were CD21 lo and CD23 hi ( Fig. 3h-j) , consistent with the previously defined naturally occurring anergic An1 cells [28] . In contrast, VH125.C57BL/6-H2g7 Insulin lo B cells were distributed in all major splenic B cell compartments, consistent with the possibility they are ignorant of ambient antigen. Importantly, both the Insulin hi and Insulin lo B cell populations in VH125.NOD mice had higher surface IgM levels (Fig. 3c) , and occurred in all major splenic B cell populations (Fig. 3h-j) , consistent with lack of anergy.
IBCs in VH125.NOD, but not VH125.C57BL/6-H2g7, mice were responsive to stimulation and had significantly decreased expression of PTEN To assess anergy we determined the responsiveness of IBC populations to BCR stimulation. To mark IBCs without stimulating them, we labelled cells with biotinylated insulin and detected them using fluorescent Fab anti-biotin (Fig. 4a) . Of note, this method did not enable the resolution of Insulin hi and Insulin lo B cell populations based on antigen binding, probably due to decreased signal amplitude. However, because the IBCs in the VH125.C57BL/6-H2g7 mice had decreased IgM expression, we believe this method identifies Insulin hi B cells when these markers are paired. Similarly, because IBCs in the VH125.NOD mice showed increased IgM expression, we believe that the approach captures at least the Insulin hi B cells, if not also the Insulin lo B cells (Fig. 4a ). When stimulated with F(ab′ ) 2 goat anti-I gM, VH125.C57BL/6-H2g7 IBCs failed to show a mobilisation of intracellular calcium (Fig. 4a) , a classic indication of anergy. VH125.NOD IBCs responded well, mobilising calcium comparably to non-IBCs in NOD and C57BL/6-H2g7 mice (Fig.  4a) . A similar relationship was seen in tyrosine phosphorylation of the BCR-proximal tyrosine kinase Syk. Although the shift was small, IBCs from VH125.C57BL/6-H2g7 mice showed significantly less induction of Syk phosphorylation than non-IBCs (Fig. 4b, c) , demonstrating a dampened signalling response consistent with anergy. Of note, the decreased change in pSyk after stimulation was in part due to elevated basal pSyk in the IBCs (mean MFI 276) compared with the non-IBCs (mean MFI 164), presumably due to chronic antigen stimulation, which maintains anergy. IBCs from VH125.NOD mice showed enhanced pSyk following stimulation compared with non-IBCs (Fig. 4b, c) , confirming they were not anergic.
Expression of PTEN is increased in anergic B cells in the MD4/ML5 transgenic mouse model and it is partially responsible for the hyporesponsiveness of anergic B cells [31, 32] . When we compared the expression of PTEN in IBCs vs nonIBCs, we found that IBCs from VH125.C57BL/6-H2g7 mice had significantly elevated levels of PTEN compared with nonIBCs (Fig. 4d, e) . However, IBCs from VH125.NOD mice showed a significantly decreased expression of PTEN compared with non-IBCs (Fig. 4d, e) , a finding consistent with the recent report of reduced PTEN expression in B cells from individuals with autoimmune systemic lupus erythematosus [33] . It should be noted that although the shifts are significant, they are small shifts in flow cytometric terms.
Taken together, these results demonstrate that IBCs in the VH125.C57BL/6-H2g7 mouse are functionally anergic, while those in VH125.NOD are not.
IBCs in VH125.NOD mice accumulate in pancreatic lymph nodes and pancreas prior to disease onset If IBCs in VH125.NOD mice have escaped tolerance and participate in disease, one might expect them to enter tissues rich in autoantigen and pertinent to the development of diabetes. Hence, we next compared the frequency of these cells in unenriched pancreatic lymph node (pLN) and pancreas samples to those in spleen samples in non-diabetic mice. As shown in Fig.  5a , b, we were able to detect both Insulin lo and Insulin hi B cells in the pLNs in VH125.NOD mice, but were only able to detect Insulin lo IBCs, which we presume are immune-ignorant and do not participate in disease, in the pLNs in VH125.C57BL/ 6-H2g7 mice. Moreover, the frequency of IBCs, particularly due to an increase in the Insulin hi B cells in the pLNs, significantly increased compared with the spleen in VH125.NOD mice, whereas the proportion of Insulin hi B cells decreased, although not significantly, in the pLNs of VH125.C57BL/ 6-H2g7 compared with spleen (Fig. 5b) . These results suggest that these cells are accumulating and/or expanding in the draining lymph nodes in NOD mice even prior to disease onset.
We rarely detected IBCs in the pancreas of VH125.C57BL/ 6-H2g7 mice and were unable to distinguish Insulin lo from Insulin hi cells in the VH125.NOD animals; we therefore refer to them as Insulin + (Fig. 5a, b) . It has been shown that the BCRs of IBCs in the pancreas are often coated with insulin, which may have inhibited our ability to discern the two populations [29] . Nonetheless, based on the cells we could detect, there was a significant increase in frequency in VH125.NOD mice of IBCs in the pancreas compared with the pLNs or spleen, suggesting that high-affinity IBCs are entering the site of autoimmune attack prior to disease onset. On the other hand, no or few IBCs (or B cells; data not shown) could be detected in the pancreas of VH125.C57BL/6-H2g7 mice (Fig.  5a, b) , suggesting that these cells are restricted to lymphoid tissues such as the spleen, and they are anergic.
IBCs in VH125.NOD mice show signs of activation prior to disease onset Hypothesising that high-affinity VH125.NOD IBCs that have broken tolerance and entered tissues rich in autoantigen may participate in disease through antigen presentation and/or autoantibody production, we next examined whether these cells exhibit markers of activation. Next, we examined whether IBCs in the two strains give rise to plasmablasts. Although both the frequency and absolute number (Fig. 5f, g ) of IBC plasmablasts in the pLNs were negligible in VH125.C57BL/6-H2g7 animals, the frequency and absolute number of IBC plasmablasts were significantly elevated in VH125.NOD mice (Fig. 5f, g ). Furthermore, we were able to detect insulin-specific autoantibodies in VH125.NOD but not VH125.C57BL/6-H2g7 animals, and these were increased compared with wild-type NOD mice (Fig. 4h) . Hence, these findings indicate that the IBCs in disease-prone VH125.NOD, but not disease-resistant VH125.C57BL/6-H2g7, mice accumulate in the pancreas and pLNs, where they become activated and probably produce autoantibodies prior to disease development.
Discussion
Previous studies have demonstrated a critical role for islet antigen-reactive B cells in the development of type 1 diabetes in the NOD mouse, and have implicated B cells in human type 1 diabetes. Studies in humans have further documented the occurrence of high-affinity IBCs in the peripheral blood of healthy individuals and shown that these cells leave the anergic compartment in blood prior to the development of type 1 diabetes [12] . Although the destination of these cells has not been fully elucidated, preliminary studies suggest that high-affinity IBCs in humans may relocate to the pLNs and pancreas and display an activated phenotype. This possibility is suggested by the histological detection of B cells in the pancreas, particularly in early-onset diabetes [34] . Due to the inherent limitations in studying this process in humans, we undertook the analysis in VH125.NOD mice and here report results that support the hypothesis and further suggest that IBCs become activated prior to arrest in the pancreas.
The results of this study provide new clarity regarding the status of IBCs in health and type 1 diabetes-prone settings. We demonstrate that, in disease-resistant settings, high-affinity IBCs can escape central tolerance, inhabiting the periphery where they are phenotypically and functionally anergic, similar to studies in healthy individuals [12] . However, previous studies have suggested that these B cells in the Tg125 mouse are also anergic in NOD animals, despite their requirement for disease [6, 15, 18] . This conundrum is clarified by the findings reported here that high-affinity IBCs lose anergy when they make up only a low percentage of the repertoire in NOD mice, avoiding the artefacts associated with using total-BCR-transgenic mice. Our studies demonstrate that IBCs in NOD mice are less efficiently eliminated by central tolerance mechanisms, occurring in the periphery at a seven-to eightfold higher frequency, progressively accumulate from birth in the spleens of these mice and then further accumulate in the pLNs and pancreas prior to disease onset. They occupy all major B cell compartments in the spleen and are not anergic, as indicated by high mIgM expression, a robust response to BCR stimulation and the upregulation of activation markers CD86 and CD69. The ability of highaffinity IBCs in the VH125.NOD mouse to upregulate CD86 suggests that these cells may participate in disease through antigen presentation to T cells, something that has already been shown in vitro despite claims they are anergic [18, 35] .
In addition, our results are also novel in that IBCs from NOD mice showed normal calcium fluxes after addition of F(ab′) 2 anti-IgM, while B6 IBCs did not, consistent with an absence and presence of anergy, respectively. A previous study claimed, based on an a lack of calcium flux after stimulation with monomeric insulin, that IBCs in NOD mice were anergic [18] . However, a multitude of studies have shown that the induction of calcium responses by B cells requires crosslinking of BCRs, something that monomeric insulin is incapable of doing. This may explain why our results differ.
This study also raises an important question regarding whether and how the immune system perceives soluble monomeric autoantigens. There is general agreement that the induction of BCR signalling, like that of other immunoreceptor tyrosine-based activation motif (ITAM)-containing receptors, requires receptor aggregation. Classical studies have shown that antigen valence is critical for induction of B cell tolerance in vitro [36, 37] . It is likely that tolerance measured in these models reflects anergy. In view of this dependency and the demonstrated requirement for chronic antigen exposure to induce and maintain anergy [38] , it seems most likely that this response requires BCR aggregation. How could this occur in the VH125 model, where the autoantigen is monomeric? An obvious possibility is that B cells see insulin that is cellassociated by virtue of binding to the ubiquitous insulin receptor, CD220. However, the parent hybridoma, 125, antibody has been shown not to bind insulin that is associated with its receptor [22] . Another possibility is that these B cells recognise insulin that is associated with BCRs on other IBCs. This too is unlikely because the VH125 expressed on all B cells in this transgenic mouse would direct specificity of all IBCs to the same epitope regardless of light chain usage. Resolution of this question will clearly require more study.
In conclusion, comparative analysis of IBC status in diseaseprone VH125.NOD and disease-resistant VH125.C57BL/6-H2g7 mice reveals how IBCs are likely to play a role in the development of type 1 diabetes, acting before the appearance of autoantibodies. This may provide a rationale for targeting these cells in the clinic to prevent type 1 diabetes, and provide essential tools for evaluating the efficacy and mode of action of candidate antigen-specific therapies.
